Catheter ablation of AF  safety and efficacy in DM patients is similar to general population , especially when performed in younger patients with satisfactory glycemic control .
Catheter ablation of AF reduces the amount of patients requiring AADs , an additional benefit in this population commonly exposed to adverse effects of AF pharmacological treatments
AIMS Diabetes mellitus ( DM ) and atrial fibrillation ( AF ) share pathophysiological links , as supported by the high prevalence of AF within DM patients .
Catheter ablation of AF ( AFCA ) is an established therapeutic option for rhythm control in drug resistant symptomatic patients .
Its efficacy and safety among patients with DM is based on small population s , and long-term outcome is unknown .
The present systematic review and meta- analysis aims to assess safety and long-term outcome of AFCA in DM patients , focusing on predictors of recurrence .
Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.
OBJECTIVES This study was design ed to investigate the potential of circumferential pulmonary vein ( PV ) ablation for atrial fibrillation ( AF ) to maintain sinus rhythm ( SR ) over time , thus reducing mortality and morbidity while enhancing quality of life ( QoL ) . BACKGROUND Circumferential PV ablation is safe and effective , but the long-term outcomes and its impact on QoL have not been assessed or compared with those for medical therapy . METHODS We examined the clinical course of 1,171 consecutive patients with symptomatic AF who were referred to us between January 1998 and March 2001 . The 589 ablated patients were compared with the 582 who received antiarrhythmic medications for SR control . The QoL of 109 ablated and 102 medically treated patients was measured with the SF-36 survey . RESULTS Median follow-up was 900 days ( range 161 to 1,508 days ) . Kaplan-Meier analysis showed observed survival for ablated patients was longer than among patients treated medically ( p < 0.001 ) , and not different from that expected for healthy persons of the same gender and calendar year of birth ( p = 0.55 ) . Cox proportional-hazards model revealed in the ablation group hazard ratios of 0.46 ( 95 % confidence interval [ CI ] , 0.31 to 0.68 ; p < 0.001 ) for all-cause mortality , of 0.45 ( 95 % CI , 0.31 to 0.64 ; p < 0.001 ) for morbidities mainly due to heart failure and ischemic cerebrovascular events , and of 0.30 ( 95 % CI , 0.24 to 0.37 ; p < 0.001 ) for AF recurrence . Ablated patients ' QoL , different from patients treated medically , reached normative levels at six months and remained unchanged at one year . CONCLUSIONS Pulmonary vein ablation improves mortality , morbidity , and QoL as compared with medical therapy . Our findings pave the way for r and omized trials to prospect a wider application of ablation therapy for AF
Catheter ablation of AF  safety and efficacy in DM patients is similar to general population , especially when performed in younger patients with satisfactory glycemic control .
Catheter ablation of AF reduces the amount of patients requiring AADs , an additional benefit in this population commonly exposed to adverse effects of AF pharmacological treatments
AIMS Diabetes mellitus ( DM ) and atrial fibrillation ( AF ) share pathophysiological links , as supported by the high prevalence of AF within DM patients .
Catheter ablation of AF ( AFCA ) is an established therapeutic option for rhythm control in drug resistant symptomatic patients .
Its efficacy and safety among patients with DM is based on small population s , and long-term outcome is unknown .
The present systematic review and meta- analysis aims to assess safety and long-term outcome of AFCA in DM patients , focusing on predictors of recurrence .